Outcomes
Outcomes employers can measure.
Real-world results from HV Health members with Type 2 Diabetes and/or Prediabetes across employer populations (2023–2024).
Average HbA1c Reduction
-1.6%
from baseline
At 12 months · n = 3,412
Average Weight Loss
-7.8%
of body weight
At 12 months · n = 3,412
Members Achieving HbA1c < 7%
63%
reached target range
At 12 months · n = 2,756
Program Engagement
78%
Members active at 90 days
Across employer populations
Methodology
Outcomes reflect real-world data collected from HV Health members enrolled through employer-sponsored benefit programs between 2023 and 2024. Members included have a documented diagnosis of Type 2 Diabetes and/or Prediabetes.
HbA1c and weight metrics are reported at 12 months of continuous enrollment. The HbA1c < 7% cohort reflects members with a baseline HbA1c at or above 7%. Engagement is defined as member activity at the 90-day mark following enrollment.
Sample sizes (n) represent members with available follow-up data at the reported timepoint. Individual results vary; these figures represent cohort averages and should not be interpreted as a guarantee of individual outcomes.
Evidence
Built on real-world clinical and commercial performance
Our approach is continuously optimized using real-world patient outcomes and engagement data across multilingual populations.
10,000+
Patients supported
Unique individuals cared for through HolaVida Health
73%
Female patients
Reflecting the populations we serve
68%
Age 35–64
Working-age adults in their prime years
3+
Languages
English, Spanish, and Portuguese